Apellis Pharmaceuticals Stock
Apellis Pharmaceuticals Stock
Pros and Cons of Apellis Pharmaceuticals in the next few years
Pros
Cons
Performance of Apellis Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals | -2.490% | - | - | - | - | - | - |
| Rockwell Medical Inc. | 2.380% | -6.480% | 9.890% | -28.205% | -21.437% | -84.031% | -96.909% |
| Gritstone Oncology Inc | 2.140% | -18.757% | -69.521% | -70.915% | -62.352% | -90.305% | - |
| Innoviva Inc. | 0.740% | 0.730% | 2.985% | 32.692% | -5.479% | 40.102% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Peering into the financial statements of a company like Apellis Pharmaceuticals, one would quickly notice that it's a company with substantial market interest, evidenced by a market capitalization in the billions. However, a glimpse reveals that the company is navigating through some challenging waters, characterized by substantial EBITDA losses and a currently inoperative P/E ratio due to negative earnings. It's not uncommon to see such financial landscapes in the pharmaceutical industry, especially within companies focusing on research and development.
The initial financial snapshot of Apellis Pharmaceuticals presents a mix of opportunities and concerns. While a high market capitalization of approximately $5.78 billion signifies strong market confidence, the absence of P/E and PEG ratios indicate a lack of profitability in the recent past. The targeted share price of $67.81 suggests optimism about the company's future prospects. That being said, negative values in profit margins and operating margins, coupled with a significant EBITDA loss, paint a picture of a company that is currently not generating profit from its operations.
The financial ratios underscore a company yet to reach profitability, with Return on Assets (ROA) and Return on Equity (ROE) being negative. However, an increase in year-over-year quarterly revenue growth hints at an expanding market share or rising demand for the company's products.